Platforms · Access · Governance
Organoid Grid
A publication about who builds the platforms that run computation on living tissue, who can actually get access to them, and who decides what is permissible. We read vendor claims against published specifications, and we take the governance questions as seriously as the engineering.
Latest analysis
August 9, 2026 The learned stimulation policy, and who gets to certify itA Sherbrooke team trains a reinforcement-learning agent to control an epiretinal implant, exploiting the smeared phosphenes it used to fight. Done in silico on virtual patients, it is a clean look at the write side of neural interfaces and the oversight it lacks.
August 9, 2026
Loihi 2 sparse coding, read against the wetware energy pitch
A Mercedes-Benz and Lubeck team publishes the first convolutional Locally Competitive Algorithm on Intel's Loihi 2 and measures it against a GPU. The dynamic-energy wins are real, and they land on the exact selling point biological-computing vendors lead with.
August 8, 2026
Arrayed screens and who can ask why tissue works
A placental CRISPR screen works because it is arrayed, one perturbation per well, since fusion and hormone secretion cannot be cleanly attributed from a conventional pooled sequencing library. The same non-cell-autonomous problem shapes who can interrogate emergent neural-organoid function, and it favours whoever owns the functional phenotyping instrumentation.
August 8, 2026
Open phenotyping tools and the oversight gap
A free, largely no-code workflow for quantifying 3D spheroids and organoids genuinely lowers the barrier to measurement. But its user-tunable segmentation and image-derived feature set reveal how open tooling can leave the standard fragmented, and risk becoming a stand-in for the functional readout that neural-tissue oversight would actually require.
August 7, 2026
The wetware cloud, read from the vendor's own pages
Cortical Labs now sells browser access to living neurons alongside the CL1 device. We read the vendor's public claims against the research it links, and ask who is left in the oversight loop when the lab requirement disappears.
August 7, 2026
Reward-modulated plasticity gets a regret bound, in silicon
A new arXiv paper proves the first regret guarantee for neuroevolution with an inner loop of reward-modulated Hebbian learning. The mechanism it formalizes in software is the one biological computing platforms attribute to living neurons, which cuts in two directions.
August 6, 2026
When scale becomes the moat for tissue
A commercial bioreactor grant describes making thousands of identical immunocompetent tumoroids from patient samples using controlled aggregation and low-shear perfusion. If that scale is real, the vendor who owns the process owns access, and for neural tissue the count is where the ethics turns heavy.
Start here
Standing explainers that do not go stale. Read the comparison first if this field is new to you.
The comparison
Biocomputing platforms, compared honestly
A dated, vendor-neutral comparison of the platforms you can actually access, the metrics that matter, and the caveats vendors leave out.
Survey
The biological-compute platform landscape, compared
Every platform you can currently reach, on one page, with the access model and the numbers that matter.
Vendor
Cortical Labs
The CL1 system: what it is, what it costs to run, and what the published results support.
Vendor
FinalSpark
The Neuroplatform remote-access model, and what running experiments over the internet changes.
Sections
Section
Platforms
The commercial and academic platforms offering access to living neural tissue, what each one actually provides, and how to read a spec sheet that was written to sell.
Section
Ethics and governance
Moral status, oversight, consent, and the policy vacuum the field is operating in.
Section
Analysis
Daily readings of new research, each asking what the work changes for this field.
How we work
We compare platforms on published specifications and peer-reviewed results, never on marketing copy, and we date every comparison because this market moves. Where a vendor funds or authors the work we are citing, we say so. On the ethics side we distinguish what is currently regulated from what is merely customary, and we do not present a philosophical position as a settled finding. The full method, including how pieces are selected and produced, is on the about page.